I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, TUS-PHARMA (000590.SZ) released its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 115 million yuan and 149 million yuan, a year-on-year turnaround from profit to loss. During the reporting period, affected by market environment and other factors, the company's total operating revenue declined compared to the same period last year, coupled with rising prices of some raw and auxiliary materials, leading to a decrease in overall gross profit margin and profitability
